Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16466450 | 1.00 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL20612426 | 1.00 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL522558 | 0.89 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL522557 | 0.89 | MEN1 (0.56) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL8251750 | 0.89 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16408319 | 0.87 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL4970964 | 0.87 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| Alanine SCHEMBL8913599 | 0.86 | SMN1; SMN2 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL29267284 | 0.86 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL16408312 | 0.85 | MEN1 (0.54) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024017251-A1 | MACROCYCLE FOR INHIBITING AND INDUCING EGFR DEGRADATION AND PREPARATION METHOD FOR AND USE OF MACROCYCLE | 江苏恒瑞医药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| EP-2906543-B1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | UNIV ASTON (GB) | 2019-01-02 | — | — | EP | disclosed |
| EP-2906543-B1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | UNIV ASTON (GB) | 2019-01-02 | — | — | EP | disclosed |
| CN-104837821-B | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | 阿斯顿大学 | 2018-11-13 | — | — | CN | disclosed |
| US-9656978-B2 | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | ASTON UNIVERSITY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9656978-B2 | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | ASTON UNIVERSITY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9656978-B2 | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | ASTON UNIVERSITY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-20150259310-A1 | Acylpiperazines as Inhibitors of Transglutaminase and Their Use in Medicine | ASTON UNIVERSITY (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259310-A1 | Acylpiperazines as Inhibitors of Transglutaminase and Their Use in Medicine | ASTON UNIVERSITY (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259310-A1 | Acylpiperazines as Inhibitors of Transglutaminase and Their Use in Medicine | ASTON UNIVERSITY (GB) | 2015-09-17 | — | — | US | disclosed |
| EP-2906543-A1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | Aston University (GB) | 2015-08-19 | — | — | EP | disclosed |
| CN-104837821-A | Acylpiperazines as inhibitors of transglutaminase and their use in medicine | UNIV ASTON | 2015-08-12 | — | — | CN | disclosed |
| WO-2014057266-A1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057266-A1 | ACYLPIPERAZINES AS INHIBITORS OF TRANSGLUTAMINASE AND THEIR USE IN MEDICINE | ASTON UNIVERSITY (GB) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259310-A1 | Acylpiperazines as Inhibitors of Transglutaminase and Their Use in Medicine | ENPEP, ENPP2, MMP17 | MEN1 1690/4885KMT2A 1957/4885NPSR1 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.